---
title: "Evolocumab cuts MACE risk, even in patients with no prior events"
date: "2026-01-26T10:20:26.000Z"
publishedDate: "26 janvier 2026"
summary: "Use of the PCSK9 inhibitor evolocumab on a background of high-intensity cholesterol lowering regimen has been shown to reduce the risk of major adverse cardiovascular events (MACE) in patients at high cardiovascular risk but who have no history of myocardial infarction (MI) or stroke. This is the headline finding from the VESALIUS-CV trial, a randomised, [&#8230;] The post Evolocumab cuts MACE risk, even in patients with no prior events appeared first on Cardiovascular News ."
importance: ""
sourceUrl: "https://cardiovascularnews.com/evolocumab-cuts-mace-risk-even-in-patients-with-no-prior-events/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2026-01-26-evolocumab-cuts-mace-risk-even-in-patients-with-no-prior-events"
imageUrl: "http://cardiovascularnews.com/wp-content/uploads/sites/14/2026/01/Erin-A.-Bohula-at-LBS-1-briefing.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/evolocumab-cuts-mace-risk-even-in-patients-with-no-prior-events/"
---

![Evolocumab cuts MACE risk, even in patients with no prior events](http://cardiovascularnews.com/wp-content/uploads/sites/14/2026/01/Erin-A.-Bohula-at-LBS-1-briefing.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/evolocumab-cuts-mace-risk-even-in-patients-with-no-prior-events/*

## L’essentiel

Use of the PCSK9 inhibitor evolocumab on a background of high-intensity cholesterol lowering regimen has been shown to reduce the risk of major adverse cardiovascular events (MACE) in patients at high cardiovascular risk but who have no history of myocardial infarction (MI) or stroke. This is the headline finding from the VESALIUS-CV trial, a randomised, [&#8230;] The post Evolocumab cuts MACE risk, even in patients with no prior events appeared first on Cardiovascular News .

## Lien source

https://cardiovascularnews.com/evolocumab-cuts-mace-risk-even-in-patients-with-no-prior-events/
